On Friday, April 10, Rutgers practitioners at University Hospital received the first FDA approval for this treatment in New Jersey, and have thus far treated 17 patients with convalescent plasma. FDA approval is pending for the use of this treatment for additional patients.
The effectiveness of this treatment is not yet known, though similar treatment has been studied for Ebola and the MERS virus. Practitioners and researchers will monitor and investigate the progress of COVID-19 patients who receive this treatment.
“The use of convalescent plasma – blood plasma from individuals who have recovered from COVID-19 – presents real hope for saving lives,” said Marc Klapholz, Chair of the Department of Medicine at Rutgers New Jersey Medical School and University Hospital, and the Principal Investigator for the use of Convalescent COVID-19 plasma.
“In our battle against the COVID-19 virus, we are excited to be trialing this potential life-saving therapy in partnership with Rutgers New Jersey Medical School. This treatment plan has been used for more than 100 years to address disease outbreaks for other conditions, and we’re optimistic that it will save lives,” said Shereef Elnahal, President and CEO of University Hospital.
People interested in donating plasma must have had a confirmed positive test for COVID-19 from a lab or health facility and be eligible to donate blood. They can reach the Rutgers and University Hospital COVID-19 Treatment Group at 973-972-5474 or via email at email@example.com.
Story originally appeared in Rutgers Today.